恒瑞医疗 网址: www.hrmedical.com.cn

专业文献

callispheres载药微球治疗中晚期非小细胞肺癌短期疗效分析-ag捕鱼平台

文字: 2020-12-18    浏览次数:275    


abstract

objective: to evaluate the short-term efficacy of callisphere drug-eluting beads (deb) in the treatment ofadvanced non-small cell lung cancer.目的:观察callispheres载药微球(drug-eluting beads,deb)在中晚期非小细胞肺癌治疗中的短期疗效与安全性。
methods: from june 2017 to march 2019,36 patients with advanced non-small cell lung cancer, treated withdrug-eluting beads (callisphere microspheres)-bronchial arterychemoembolization (deb-bace), were included in the current retrospective study. all patients were followed up for 3 ~ 25 months after surgery. the modified response evaluation criteria in solid tumors (mrecist) was used to evaluate the efficacy. the blood routine examination results, liver function, kidney function andlocal tumor response were compared before and after surgery; postoperative complications were analysed.方法:回顾性收集2017年6月~2019年3月在本院进行载药微球-支气管动脉化疗栓塞(deb-bace)治疗的36例中晚期非小细胞肺癌患者的资料,所有患者术后均随访3~25个月,采用改良实体瘤临床疗效评价标准(modified response evaluation criteria in solid tumor,mrecist)评估治疗效果,比较术前、术后患者血常规、肝、肾功能、肿瘤局部反应及术后并发症等指标。
results: all patients were treated with callisphere, and the technical success rate was 100%. there was significant rise in the level of wbc, plt, alt, ast, tbil and obvious decline of hb and alb after deb-bace. no statistic difference was observed in rbc, scrand egfr. according to the mrecist criteria, the objective response rates were 77.78%, 69.45%, 58.33%, and the disease control rates were 94.45%, 88.89%, 83.33% respectively at 1, 3, 6 months after deb-bace treatment.结果:所有患者介入治疗的成功率为100% ,deb-bace 术后1周白细胞(wbc)、血小板(plt)、谷丙转氨酶(alt)、谷草转氨酶(ast)、总胆红素(tbil)水平有所上升,血红蛋白(hb)及白蛋白(alb)水平有所降低,红细胞(rbc)、血清肌酐(scr)、肾小球滤过率(egfr)无统计学差异。术后1个月肿瘤客观缓解率为77.78%,疾病控制率为94.45%。术后3个月肿瘤客观缓解率为69.45%,疾病控制率为88.89%。术后6个月肿瘤客观缓解率为58.33%,疾病控制率为83.33%。
conclusions: the short-termefficacy and safety of callisphere microspheres on advanced non-small cell lung cancer are acceptable.结论:callispheres载药微球治疗中晚期非小细胞肺癌短期疗效良好,安全性较高。